Company Filing History:
Years Active: 2016
Title: Laura Caboni: Innovator in Androgen Receptor Research
Introduction
Laura Caboni is a distinguished inventor based in Blackrock, Ireland. She has made significant contributions to the field of androgen receptor research, particularly in developing novel therapeutic strategies for androgen-dependent conditions. Her work is crucial in addressing the challenges associated with current prostate cancer treatments.
Latest Patents
Laura Caboni holds a patent for "Androgen receptor ligands - Non ligand binding pocket antagonists for the human androgen receptor." This innovative patent focuses on a class of non-steroidal, small molecule AR antagonists that inhibit the transcriptional activity of the androgen receptor through non-ligand binding pocket-mediated modulation. The research highlights the potential of these antagonists as an alternative approach to classical prostate cancer therapy, demonstrating full antagonism with low micromolar potency and high selectivity over estrogen and glucocorticoid receptors.
Career Highlights
Laura is affiliated with the College of the Holy and Undivided Trinity of Queen Elizabeth, located near Dublin. Her academic and research endeavors have positioned her as a key figure in the exploration of androgen receptor modulation and its implications for therapeutic applications.
Collaborations
Laura collaborates with notable colleagues, including David George Lloyd and Darren Fayne. Their combined expertise enhances the research efforts in the field of androgen receptor antagonism.
Conclusion
Laura Caboni's innovative work in androgen receptor research represents a significant advancement in the search for effective treatments for prostate cancer and other androgen-dependent conditions. Her contributions are paving the way for new therapeutic strategies that could improve patient outcomes.